retatrutide type 2 diabetes trial results Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide vs Ozempic: Clinical Trial

It supports the release of insulin to lower blood sugar without causing it to drop too low

Theres no one-size-fits-all, but little things count

Tirzepatide is not recommended during pregnancy or lactation, and women of reproductive potential should discontinue treatment if pregnancy is recognized

protein-rich foods like eggs, meat, and tofu

Glucagon-like peptide-1 (GLP-1) receptor agonists were investigated in 43 (72.9%) studies (Figure 4), with liraglutide being the agent used in 54.2% of all studies

Referral to endocrinology, cardiology, or lipid specialists may be warranted for complex cases involving multiple cardiovascular risk factors, familial hypercholesterolemia, severe hypertriglyceridemia (500 mg/dL), or inadequate response to initial therapy